PharmaCyte Biotech Inc (PMCB)

[Daphnis]

PMCB’s Cell-in-a-Box technology and the positive shift in the medical landscape for such treatment presents an extraordinarily high value following FDA approval and upon up listing to NASDAQ (this is happening within or at and around a years time from today) Nano cellular encapsulation treatments are currently and by far thee best option against tumors. The trendy and compatible focus on gene editing and the adaptive immune treatments are so far unable to handle the hostile environment of a cancerous tumor.

“...there were 25% more deals worth over $1 billion up front. Many of them underscored the continued popularity of targeted oncology, immunology and rare-disease assets, as well as an increasing confidence in experimental therapy platform technologies using oligonucleotide, gene- or cell-therapy modalities.”